Interview with Sena Maria, Founder, Microdosing For Resilience
Similar Posts
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #PsychedelicStocks #Psilocybin
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES!
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES
Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202
In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.
In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.
This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.
The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.
Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.
Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.
Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5
Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage
Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psilocybin #DMT #Psychedelics
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD
Interview with Evan Levine, PsyBio Therapeutics
In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.
![Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-47-600x338.jpeg)
Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]
Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).
In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology
I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#CompassPathways #CMPS #MindMed
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #PsychedelicStocks #Psilocybin
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES!
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES
Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202
In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.
In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.
This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.
The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.
Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.
Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.
Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5
Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage
Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psilocybin #DMT #Psychedelics
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD
Interview with Evan Levine, PsyBio Therapeutics
In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.
Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]
Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).
In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology
I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#CompassPathways #CMPS #MindMed
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #PsychedelicStocks #Psilocybin
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES!
Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES
Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202
In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.
In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.
This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.
The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.
Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.
Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.
Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5
Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage
Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psilocybin #DMT #Psychedelics
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD
Interview with Evan Levine, PsyBio Therapeutics
In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.
Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]
Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).
In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology
I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#CompassPathways #CMPS #MindMed
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.